ClinicalTrials.gg
Not yet recruitingNCT06547138SSIHLVERUpdated Nov 6, 2026

Pilot Study on the Effectiveness and Safety of OPTILENE® SILVER MESH ELASTIC in Prevention of Surgical Site Infection (SSI) and Incisional Hernia (IH)

An observational study in Abdominal Aortic Aneurysm and Morbid Obesity, sponsored by Aesculap AG. Not yet recruiting at 5 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Aesculap AG (part of B. Braun) · Observational

How we know

Updated Nov 6, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
110
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Aortic Aneurysm, Abdominal with a site in Spain — 11 open to participants now, 14 under way, none of them phase 3. Aortic Aneurysm, Abdominal · Spain.

Planned enrollment
18th of 24
110 · median 201
Started
2027
the only one that year
Observational
24 of 35
7 open now
Primary completion
2028-03
later than 7 of 13 live
Registered
31st of 35
by date
Lead sponsor
1 of 35
Aesculap AG

Among the 35 studies in Aortic Aneurysm, Abdominal with a site in Spain, this one is the 18th largest by planned enrollment of the 24 observational ones that give a count, is the only one that started in 2027, is one of 24 observational ones, reaches primary completion later than 7 of the 13 other live ones, and was the 31st registered.

Aortic Aneurysm, Abdominal

467 studies on the registry are indexed under Aortic Aneurysm, Abdominal; 99 are open to participants now.

Browse Aortic Aneurysm, Abdominal studies →

Open to participants now

11 of the 35 studies in Aortic Aneurysm, Abdominal with a site in Spain are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 66 Aortic Aneurysm, Abdominal studies recruiting now, 52 (79%) set no upper age limit and 3 (5%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Aortic Aneurysm, Abdominal with a site in Spain, or all of them as a file.
02

Study summary

The aim of the study is to describe the effectiveness of Optilene® Silver Mesh Elastic on prevention of surgical site infection (SSI) at 6 months follow-up in patients undergoing urgent laparotomy by collecting clinical data on the SSI rates, IH rates and overall clinical performance of Optilene® Silver Mesh Elastic used for the prevention of incisional hernia as prophylactic mesh in patients that require urgent median laparotomy in clinical routine.

03

Conditions studied

  • Abdominal Aortic Aneurysm
  • Morbid Obesity

Keywords

  • urgent, primary median laparotomy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

High-risk patients according to the professional criteria (such as but not limited to: age, nutrition, body mass index, comorbidities, etc.) who are undergoing prophylactic mesh implantation to avoid surgical site infection after an emergency or urgent intra-abdominal laparotomy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (18 years or older)
  • Surgical procedure requiring urgent, primary median laparotomy, which are classified as "Class III/Contaminated" or "Class IV/Dirty-Infected" regarding the CDC classification.

These include but are not limited to:

  • Vascular surgery
  • Colon and rectum
  • Hepatobiliary
  • Gastrointestinal
  • Gynecology
  • Urology
  • Abdominal Aortic Aneurysm (AAA) repair
  • Right hemicolectomy
  • Left hemicolectomy
  • Sigmoidectomy
  • Anterior resection
  • Abdominoperineal amputation
  • Exploratory laparotomy
  • Cholecystectomy
  • Cholecystectomy and choledocotomy

    • Written

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Breast feeding
  • Patients \< 18 years old or patients who are still in the growth phase
  • Contaminated and infected areas
  • to silver
  • Direct contact with the viscera
  • Previous allergic reactions to components of the device
  • Patient with previous laparotomy
  • Transverse laparotomy
  • Patients with previous hernia repair
  • Simultaneous participation in another clinical trial (drug or medical studies)
  • Patients with active oncologic treatment (chemo and radiotherapy)
  • Underlying disease
  • Recent cardiovascular complication
  • Gynecology surgery
  • Urology surgery
  • Vascular surgery
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
110 participants (estimated)
Patient registry
No

Groups and cohorts

  • Optilene® Silver Mesh Elastic

    Prophylactic mesh in high-risk patients

    Device: Prophylactic mesh

Interventions

  • DeviceProphylactic mesh

    Prevention of incisional hernia after a prophylactic mesh in high-risk patients

06

What researchers measure

Primary outcomes

  1. Surgical Site Infection (SSI) A2/A3 rate

    SSIs remain a significant clinical problem as they are associated with substantial mortality and morbidity and impose severe demands on healthcare resources. Centers for Disease Control and Prevention Surgical Site Infection (SSI) Classification System differentiates Superficial SSI (A1), Deep Incisional SSI (A2) and Infection with involvement of organs/body cavities (A3). Only cases of A2 and A3 are considered for the Primary Outcome and are compared to rates from reference literature

    Time frame: at 6 months follow-up

Secondary outcomes

  1. Cumulative rate of of postoperative complications during the study period

    Numbers of all postoperative complications such as mortality, burst abdomen, bowel obstruction, bulging, necrosis, fistula, wound dehiscence, hematoma, seroma, peritonitis are added to the overall complication rate that is observed over the postoperative course

    Time frame: at discharge (up to 10 days after surgery), 1 month, 6 months, 1 year and 2 year follow-up

  2. Cumulative Surgical Site Infection (SSI) A2/A3 rate during the study period

    Number of the Surgical Site Infection (SSI) (only A2 and A3) rate at every follow-up

    Time frame: at 1 month, 1 year and 2 year follow-up.

  3. Incisional hernia (IH) rate during the study period

    Incisional hernia (IH) is a protrusion of tissue that forms at the site of a healing surgical scar. Incisional hernia refers to abdominal wall hernia at the site of a previous surgical incision.

    Time frame: repeatedly at 6 months, 1 year and 2 year follow-up.

  4. Length of hospital stay

    Number of days the patient has to stay in hospital after the surgery

    Time frame: at discharge (approximately up to 10 days after surgery)

  5. Development of Pain: Visual Analogue Scale (VAS)

    This parameter will be noted using the Visual Analogue Scale (VAS) which state "0" at one end representing "no pain" and "100" at the opposite end representing "heavy pain".

    Time frame: at discharge (approximately up to 10 days after surgery), 1 month, 6 months, 1 year and 2 year follow-up, using the VAS score

  6. Time to return to work

    The number of days needed to return to work after the surgery of the individual patient is documented

    Time frame: at all postoperative examinations with a single value for each individual patient

  7. Handling of the Optilene® Silver Mesh Elastic

    The handling will be evaluated using a questionnaire (Likert-type scale) with the dimensions Tensile Strength, Absence of memory effect, Elasticity, Stiffness, Surface weight, Thickness, Ease of being fixed with suture, Ease of package extraction as well as an overall opinion in five evaluation levels (excellent=1, very good=2, good=3, satisfied=4, poor=5)

    Time frame: intraoperatively

07

Study locations

5 sites
  • Hospital Universitari Germans Tries i Pujol
    Badalona, 08916, Spain
    • Joan Francesc Julián, Dr. · Contact
    • Joan Francesc Julián, Dr. · Principal investigator
  • Hospital Municipal Badalona
    Badalona, Spain
    • Jorge Marroquin, Dr. · Contact
    • Jorge Marroquin, Dr. · Principal investigator
  • Hospital Comarcal Sant Jaume de Calella
    Calella, 08370, Spain
    • Paqui Vasco, Dr. · Contact
    • Paqui Vasco, Dr. · Principal investigator
  • Hospital de Mataró
    Mataró, 08304, Spain
    • Berhanu Chimdi, Dr. · Contact
    • Berhanu Chimdi, Dr. · Principal investigator
  • Hospital Fundació Esperit Sant
    Santa Coloma de Gramenet, 08923, Spain
    • Daniel Troyano Escribano, Dr. · Contact
    • Daniel Troyano Escribano, Dr. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2027; primary completion for Mar 2028, 13 months later.

Of 91 observational studies under Aortic Aneurysm, Abdominal, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 83. This study's planned 13 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: start Sep 2026 → Feb 2027, primary completion Oct 2027 → Mar 2028 and completion Sep 2028 → Sep 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2024
First posted
Aug 9, 2024
StartEst.
Feb 2027was Sep 2026
Primary completionEst.
Mar 2028was Oct 2027
CompletionEst.
Sep 2029was Sep 2028
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 2026→Feb 2027
Nov 6, 2026
Primary completion
Oct 2027→Mar 2028
Nov 6, 2026
Study completion
Sep 2028→Sep 2029
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Start date Sep 2026→Feb 2027
    Primary completion Oct 2027→Mar 2028
    Study completion Sep 2028→Sep 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06547138
Lead sponsor
Aesculap AG
Collaborators
B.Braun Surgical SA
Responsible party
Sponsor
First posted
Aug 9, 2024
Start date
Feb 2027 (estimated)
Primary completion
Mar 2028 (estimated)
Completion
Sep 2029 (estimated)
Last update
Nov 6, 2026

Study contacts

Irene Fita Esteban
Contact
info@bbraun.com
+34609054401
José Manuel Molina Villar
Contact
info@bbraun.com
+34697502623
Daniel Troyano Escribano, Dr.
principal investigator · Fundació Hospital de l'Esperit Sant

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion